Subclinical synovitis is significantly more common among patients with psoriasis without musculoskeletal involvement than ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

The likelihood of reduced quality of life and high symptom burden in patients with psoriasis was similar across those with low, medium, and high BSA.

Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.

The best at-home, FDA-approved red light therapy tools and panels for the face and body in 2025, according to editors, ...

Kayakalp Global, an integrative dermatology center, announced positive in vitro lab results for its Psorcure Oil, a steroid ...

High blood pressure, or hypertension, happens when the force of blood in the arteries stays high over time. It can lead to ...

The Dermatology Devices market is expected to grow at a compound annual growth rate (CAGR) of 6.5% over the forecast period, ...